Arecor Therapeutics plc (AIM:AREC)

Market Cap	25.11M +31.7%
Revenue (ttm)	5.06M +3.3%
Net Income	-8.10M
EPS	-0.22
Shares Out	37.76M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,000
Average Volume	11,322
Open	66.50
Previous Close	62.50
Day's Range	67.45 - 67.45
52-Week Range	35.40 - 100.00
Beta	-0.28
RSI	32.59
Earnings Date	Apr 20, 2026

About Arecor Therapeutics

Arecor Therapeutics plc, a clinical stage biotechnology company, develops innovative medicines that address significant unmet patient needs in the United Kingdom. The company through its proprietary reformulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo which is used to treat severe hypoglycaemia events in patients with diabetes;...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 44
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: AREC

Financial Performance

In 2024, Arecor Therapeutics's revenue was 5.05 million, an increase of 10.50% compared to the previous year's 4.57 million. Losses were -10.24 million, 19.7% more than in 2023.